Pyrrolidin-2-one derivatives for use as DP

1. A compound of the Formula I

or a pharmaceutically acceptable salt thereof;

wherein: A and C are hydrogen;

M is selected from the group consisting of optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and —(CH 2 )q-B;

wherein B is selected from the group comprising optionally substituted carbocyclic aryl, optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least one N, O or S ring atom and a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least one N, O or S ring atom;

wherein q in “—(CH 2 )q-B” is selected from 1, 2, 3 and 4;

U is (CH 2 ) p wherein p is selected from 0, 1 and 2; and

V and Q are each independently hydrogen, optionally substituted alkyl, or C 3 -C 6 cycloalkyl;

with at least one of V and Q being other than hydrogen.

2. The compound of claim 1 , wherein B is optionally substituted carbocyclic aryl.

3. The compound of claim 1 , wherein B is optionally substituted phenyl.

4. A compound of claim 1 , according to Formula II:

or a pharmaceutically acceptable salt thereof;

wherein M′ is selected from the group consisting of: optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

R is C(═O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

U is (CH 2 ) p ;

p is selected from 0, 1 and 2;

V and Q are each independently hydrogen or optionally substituted alkyl;

with at least one of V and Q being other than hydrogen.

5. The compound of claim 4 , wherein n is 1 or 2.

6. A compound of claim 1 , according to Formula III:

or a pharmaceutically acceptable salt thereof;

wherein M′ is selected from the group consisting of: optionally substituted C 1 -C 7 alkyl, C 2 -C 5 alkenyl, and C 2 -C 6 alkynyl;

R is C(═O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally alkylamine;

U is (CH 2 ) p ;

p is selected from 0, 1 and 2;

V and Q are each independently hydrogen or optionally substituted alkyl;

with at least one of V and Q being other than hydrogen.

7. The compound of claim 1 , according to Formula IV:

or a pharmaceutically acceptable salt thereof;

wherein M′ is selected from the group consisting of: optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

R is C(═O)Z; where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

U is (CH 2 ) p ;

p is selected from 0, 1 and 2;

Q is hydrogen or optionally substituted alkyl or C 3 -C 6 cycloalkyl.

8. The compound according to claim 7 , wherein:

Q is an optionally substituted C 1 -C 12 alkyl, or C 3 -C 6 cycloalkyl.

9. The compound according to claim 1 , wherein p is zero.

10. The compound of claim 4 , wherein p is zero.

11. The compound of claim 6 , wherein p is zero.

12. The compound of claim 7 , wherein p is zero.

13. A compound of claim 1 , according to Formula V:

or a pharmaceutically acceptable salt thereof;

wherein M′ is selected from the group consisting of: optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

R is C(═O)Z; where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

Q is optionally substituted alkyl, or C 3 -C 6 cycloalkyl.

14. The compound of claim 13 , wherein n is 1 and R is a para-substituent.

15. The compound of claim 13 wherein R is —C(O)OH.

16. The compound of claim 13 , wherein Q is a straight or branched C 1 -C 12 alkyl.

17. The compound of claim 13 wherein:

R is —C(O)OH is in a “para” position and n is 1.

18. The compound of claim 1 , wherein M has the formula:

wherein M′ is selected from the group consisting of: optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, and C 2 -C 6 alkynyl;

A is selected from the group consisting of: optionally substituted pyridyl, pyrrolyl, furyl (furanyl), thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 1,3,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinolizinyl, quinazolinyl, pthalazinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl and benzoquinolyl; and

R is C(═O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine; n is an integer selected from 0, 1, 2, 3, 4 and 5.

19. The compound of claim 1 , wherein M is selected from the group consisting of:

20. The compound of claim 1 , wherein M is selected from the group consisting of:

wherein R 4 is selected from the group consisting of: H, an alkyl group, and an aryl group or a salt.

21. The compound of claim 1 , wherein M is:

22. The compound of claim 1 , wherein M is:

23. The compound of claim 1 , wherein M is:

24. A compound selected from the group consisting of:

4-(3-(2S)-1-[(3R)-3-cyclohexyl-3-hydroxypropyl]-5-oxotetrahydro-1H-2-pyrrolylpropyl)benzoic acid;

4-(3-(2S)-1-[(3S)-3-cyclohexyl-3-hydroxypropyl]-5-oxotetrahydro-1H-2-pyrrolylpropyl)benzoic acid;

7-{(2S)-1-[(3R)-3-cyclohexyl-3-hydroxypropyl]-5-oxopyrrolidin-2-yl}Heptanoic acid; and

7-{(2S)-1-[(3R)-3-cyclohexyl-3-hydroxypropyl]-5-oxopyrrolidin-2-yl}Heptanoic acid, or a pharmaceutically acceptable salt thereof.

25. A compound according to formulae I2, II2, III2, IV2, V2, and V3, as shown below:

or a pharmaceutically acceptable salt thereof;

wherein A and C are hydrogen;

B is selected from the group comprising: optionally substituted carbocyclic aryl, optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least one nitrogen, oxygen or sulfur ring atom, and a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least one nitrogen, oxygen, or sulfur ring atom;

R is C(═O)Z where Z is selected from hydrogen, hydroxy, optionally substituted alkoxy and optionally substituted alkyl; or R is amino or optionally substituted alkylamine;

n is an integer selected from 0, 1, 2, 3, 4 and 5;

U is (CH 2 ) p ;

p is selected from 0, 1 and 2;

V and Q are each independently hydrogen, optionally substituted alkyl or C 3 -C 6 cycloalkyl;

with at least one of V and Q being other than hydrogen.

26. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

27. A method of treatment of a mammal suffering from a disease or disorder associated with prostaglandin deficiency, wherein the disease or disorder is chosen from: erectile dysfunction, asthma, and sexual dysfunction, comprising administering to said mammal an effective amount of a compound according to Formula I:

or a pharmaceutically acceptable salt thereof:

wherein: A and C are hydrogen;

M is selected from the group consisting of optionally substituted C 1 -C 7 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and —(CH 2 )q-B;

wherein B is selected from the group comprising: optionally substituted carbocyclic aryl, optionally substituted heteroalicyclic having from 3 to 8 ring atoms and at least on N, O or S ring atom, and a heteroaromatic group having a single ring with 5 or 6 ring atoms and at least on N, O or S ring atom;

wherein q in “—(CH 2 ) q -B” is selected from 1, 2, 3, and 4;

U is (CH 2 ) p wherein p is selected from 0, 1 and 2;

V and Q are each independently hydrogen, optionally substituted alkyl or C 3 -C 6 cycloalkyl with at least one of V and Q being other than hydrogen.

28. The method of claim 27 , wherein the disease is chosen from: preterm labor, dysmenorrhea, asthma, hypertension, a fertility disorder, undesired blood clotting, preeclampsia, eclampsia, an eosinophil disorder, undesired bone loss, sexual dysfunction, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, a sleep disorder, a gastric ulcer, inflammatory disorder and erectile dysfunction.

29. The method of claim 28 , wherein the disease is erectile dysfunction.

30. The method of claim 29 , wherein the compound is administered by intracavernosal injection.